I will be informed of any new findings developed during the 
course of this clinical research study, which may relate to my 
willingness to continue participation in the study. 
9. I have been assured that confidentiality will be preserved 
except that qualified monitors from the Food and Drug 
Administration and the National Cancer Institute may review my 
records where appropriate and necessary. Qualified monitors 
shall include assignees authorized by the Surveillance 
Committee of this institution provided that confidentiality is 
assured and preserved. My name will not be revealed in any 
reports or publications resulting from this study, without my 
expressed consent. 
10. I have been informed that should I suffer any injury as a 
result of participation in this research activity, reasonable 
medical facilities are available at this institution. I 
understand, however, that I cannot expect to receive any 
credit or reimbursement for expenses from this institution or 
any financial compensation from this institution for such 
injury. 
11. I have been informed that I should inquire of the attending 
physician whether or not there are any services, 
investigational agents or devices, and/or medications being 
offered by the sponsor of the clinical research project at a 
reduced cost or without cost. Should the investigational 
agent become commercially available during the course of the 
study, I understand that I may be required to cover the cost 
of subsequent doses. 
Costs related to my medical care including expensive tests or 
procedures that may be specifically required by this clinical 
research study shall not be my responsibility. I have been 
given the opportunity to discuss the expenses or costs 
associated with my participation in this research activity. 
13. I understand that practicing effective contraception is 
medically necessary and a prerequisite for my participation in 
this clinical research study. Should contraception be 
interrupted or if there is any suspicion of pregnancy, my 
participation in this clinical research study will be 
terminated at the sole discretion of the investigator. 
14. I may discuss questions or problems during or after this study 
with Dr. Albert Deisseroth at (713) 792-8750. In addition, I 
may discuss any problems I may have or any questions regarding 
my rights during or after this study with the Chairman of the 
Surveillance Committee at (713) 792-3220 and may in the event 
any problem arises during this clinical research contact the 
parties named above. 
Recombinant DNA Research, Volume 15 
[877] 
